Danvatirsen Plus Venetoclax

A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
24 patients (estimated)
Sponsors
Montefiore Medical Center
Collaborators
MD Anderson Cancer Center
Tags
Antisense Oligonucleotide (ASO), BCL-2 Inhibitor
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1749
NCT Identifier
NCT05986240

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.